Evidence-based articles on peptides, biomarkers, longevity science, and regulatory developments.
Featured Research
The FDA Pharmacy Compounding Advisory Committee recommended six of seven peptides, including BPC-157, TB-500 and MOTS-c, for potential inclusion on the 503A Bulks List. Here is what was decided and what it means for researchers.
Read ArticleFrom single GLP-1 agonists to dual and triple agonists, this guide explains how each generation of metabolic peptide was designed to engage more of the body's incretin system, and the biomarkers that give context.
Seven peptides were reviewed at the July 23-24, 2026 PCAC meeting, where six of seven received favorable recommendations. Here is what the process means, which peptides are affected, and what researchers should understand.
The 503A Bulks List governs which substances licensed compounding pharmacies can legally manufacture. Here is what researchers need to understand about the process and what the July 2026 review decided.
BPC-157 is one of the most researched peptides in the longevity space. Here is what the preclinical studies show, what researchers track, and why it was among the seven peptides reviewed at the July 2026 PCAC meeting.
Biomarkers are the foundation of biology-first longevity research. Here is what the key categories reveal about your biology and how they connect to longevity research protocols.
TB-500 is a synthetic analog of Thymosin Beta-4 studied for tissue repair and regenerative properties. Here is what the preclinical research shows and why it was among the seven peptides reviewed at the July 2026 PCAC meeting.
More research articles coming soon. Join the waitlist to be notified when new articles are published.
Join the WaitlistFor educational and research purposes only. Not medical advice. Always consult a licensed healthcare provider before making any health decisions.